A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

NCT05940181 | Unknown

• 1 other identifier: XKY-C-001
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This is an investigator-initiated, single-center, open label, single-arm dose escalation study of XH001 (neoantigen tumor vaccine) in combination with sintilimab for advanced solid tumors. To evaluate the safety and tolerability of XH001 combined with sintilimab in subjects with advanced solid tumors, and preliminarily evaluate the efficacy of the combination therapy in subjects with advanced solid tumors. The study will include pre-screening period (about 12 weeks), screening period (Weeks -4 to Day 1, and Week -1 to Day -1 will be baseline period), treatment period (Day 1 to Week 16 will be combination treatment period, followed by sintilimab monotherapy), and follow-up period. After signing pre-screening informed consent, tumor tissue and blood samples will be collected for gene sequencing, neoantigen prediction and vaccine preparation. During vaccine preparation, subjects will receive sintilimab (200mg, intravenous infusion, 21-day per cycle) or other antitumor therapy as deemed appropriate by the investigator. Subjects who sign and provide formal informed consent will enter the formal screening period, and qualified subjects will enter treatment period. During the treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first). The dose escalation phase follows standard 3+3 design. 9-12 subjects are expected to be enrolled at 2 given dose level.

Conditions

Solid Tumor

Keywords

cancer vaccine; mRNA; neoantigen

Outcome Measures

Primary Outcomes (3)

• MTD or Clinical recommended dose

  Baseline through 90 days after last XH001 dose, up to 6 months

• DLT

  Rate of Dose Limiting Toxicities

  Cycle 1, up to 21 days

• Incidence and degree of Adverse Events and Serious Adverse Events [Safety]

  Incidence and degree of participants with adverse events(CTCAE 5.0)

  Baseline through 90 days after last sintilimab dose, up to 1 year

Secondary Outcomes (6)

• Antigen-Specific T-cell Responses in Peripheral Blood

  Baseline through last sintilimab dose, up to 1 year

• Number of specific immune response T cells

  Baseline through last sintilimab dose, up to 1 year

• Overall Response Rate (ORR)

  up to 2 years

• Best Overall Response (BOR)

  up to 2 years

• Disease Control Rate (DCR)

  up to 2 years

Study Arms (1)

XH001+ sintilimab

EXPERIMENTAL

XH001: 2 dose level Sintilimab: 200mg iv, 21 day per cycle

Biological: XH001+ sintilimab

Interventions

XH001+ sintilimab BIOLOGICAL

During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).

XH001+ sintilimab

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Is willing and able to provide written informed consent for the trial.
• Is ≥18 years and ≤ 75 years of age on day of signing informed consent.
• Has a histologically confirmed advanced solid tumor. Subjects must have documented progression after standard therapy or is intolerant of, refuses, or is not eligible for standard therapy.
• Has at least 1 measurable disease lesion as defined by Response Evaluation Criteria in Solid Tumors.
• Has a life expectancy of ≥12 weeks.
• Has an ECOG performance status of 0-1.
• Has adequate organ function as confirmed by laboratory values listed in the main body of the protocol

You may not qualify if:

• Subject who need to receive systemic application of anti-allergic drugs for a long time, or have a history of life-threatening allergic reactions to any vaccine or drug;
• Symptomatic or rapidly progressive central nervous system metastases. Patients with extensive lung metastases resulting in dyspnea; patients with tumors close to or invading major blood vessels or nerves;
• New cerebrovascular accident (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack) within 6 months before screening;
• Subject with acute myocardial infarction within 6 months before screening, or uncontrolled angina, uncontrolled arrhythmia, severe heart failure (see Appendix 3, New York Heart Association Heart Failure Classification Criteria NYHA Class ≥ III) and other cardiovascular diseases;
• Subject who have received treatment with immunomodulatory drugs 4 times before the first vaccination day (D1), including but not limited to: IL-2, CTLA-4 inhibitors, CD40 agonists, CD137 agonists, IFN-α (except for high-risk surgical subjects who use IFN-α as adjuvant therapy, if IFN-α treatment is stopped 4 times before this trial);
• Subject who received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) before baseline;
• Subject with skin diseases (e.g., psoriasis) at baseline that may prevent the intradermal injection of vaccine into the target area;
• Subject still suffer from adverse reactions (except alopecia and platinum-induced neurotoxicity ≤ grade 2) that have not been restored to CTCAE version 5.0 grade ≤ 1 after previous anti-tumor treatment during the screening period;
• Concomitant use of steroid hormone drugs (tumor or non-tumor related diseases) is required; however, topical application (not applied to the vaccination site) or inhaled steroid drugs are required;
• Subject has an active infection or uncontrollable infection (except for simple urinary tract infection or upper respiratory tract infection) requiring systemic treatment;
• Subjects with positive human immunodeficiency virus antibody, hepatitis B surface antigen and/or hepatitis B core antibody and positive hepatitis B virus deoxyribonucleic acid \> 1000 IU/mL, hepatitis C virus antibody, Treponema pallidum-specific antibody in virological monitoring during the screening period;
• Hypertension poorly controlled on treatment (defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
• Subject with other malignant tumors within 5 years before the screening period, except for cervical carcinoma in situ, breast carcinoma in situ and cutaneous basal cell carcinoma that have received appropriate treatment and met the recovery criteria;
• Subject with a history of autoimmune diseases \[such as, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or hypothyroidism caused by chemoradiotherapy can be included), subjects with vitiligo or recovered asthma can be included without any intervention, and subjects with asthma requiring bronchodilators for medical intervention cannot be included\];
• Subject who has previously received similar therapeutic tumor vaccines;

Sponsors & Collaborators

• jianming xu: lead
• NeoCura: collaborator

Study Sites (1)

PLA General Hospital

Beijing, Beijing Municipality, 100039, China

RECRUITING

Study Officials

• Jianming XU, Dr.

  PLA General Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jianming XU, Dr.

CONTACT

86 10 66937876; jmxu2003@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director, Head of Department of Oncology

Model Details: single-center, open-label, single-arm, dose escalation exploratory study

Study Record Dates

• First Submitted: May 11, 2023
• First Posted: July 11, 2023
• Study Start: March 1, 2023
• Primary Completion: May 1, 2025
• Study Completion: December 1, 2025
• Last Updated: July 11, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)